




>>Abarelix, INN, USAN



N-Acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-*N*-methyl-L-tyrosyl-D-asparaginy-L-leucyl-*N*⁶-isopropyl-L-prolyl-D-alaninamide

DGH73-B

[183552-38-7]

Classification:XA4945

C₇₂H₉₅ClN₁₄O₁₄ M 1416.081. 1414.684073. C 61.07%; H 6.76%; Cl 2.50%; N 13.85%; O 15.82%

LHRH antagonist. Investigated in combination with a LHRH agonist for treating prostate cancer prior to conventional surgery

[186837-47-8]

Pat. Coop. Treaty (WIPO), 1996, *Indiana University Foundation*, 96 40 757; *CA*, **126**, 152828j, (*synth, pharmacol*)

Pat. Coop. Treaty (WIPO), 1997, *Pharm. Peptides Inc*, 97 22 357; *CA*, **127**, 104336w, (*use*)

Graul, A. *et al.*, *Drugs of the Future*, 1998, **23**, 1057-1061, (*rev*)